CLINICAL_TRIALS
trial_result
· 2016-01-14
Clinical Trial Update: Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis [Phase 3]
Summary
Novartis' Phase 3 trial of AIN457 (secukinumab) for quiescent non-infectious uveitis was terminated, with results posted in January 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Non-infectious Uveitis | Phase 3 | Status: TERMINATED | Results posted: 2016-01-14